Recalcati P, Perini A
Arch Sci Med (Torino). 1978 Oct-Dec;135(4):435-46.
Levels of anti-Xa and anti-thrombin III activity have been determined in a series of patients clinically definable as "thrombophiliac" and of women undergoing oestroprogestinic contraceptive treatment. The levels of plasma Co-Ep activity for potentiating anti-Xa activity on the part of differing in vitro added doses of Ep have also been determined. The fact that anti-Xa fell in more marked a fashion than the corresponding anti-thrombin III may be the humoral equivalent of a condition of plasma hypercoagulability. Treatment with coumarin derivatives may bring about an appreciable increase anti-Xa plasma levels. The significance of these variations is discussed and the sensitivity of the anti-Xa method for monitoring small dose heparin therapy, i.e. based on antithrombotic rather than anti-coagulant effect, is confirmed.
已对一系列临床上可定义为“血栓形成倾向者”的患者以及接受雌孕激素避孕治疗的女性测定了抗Xa和抗凝血酶III活性水平。还测定了不同体外添加剂量的依诺肝素（Ep）增强抗Xa活性时血浆中依诺肝素 - 凝血酶原复合物（Co - Ep）活性水平。抗Xa活性比相应的抗凝血酶III活性更显著下降这一事实，可能是血浆高凝状态的体液学等效表现。香豆素衍生物治疗可能会使抗Xa血浆水平显著升高。讨论了这些变化的意义，并证实了基于抗血栓形成而非抗凝作用监测小剂量肝素治疗的抗Xa方法的敏感性。
